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ABSTRACT 
Patients with chronic kidney disease (CKD) often suffer from malnutrition and protein-
energy wasting (PEW) resulting in poor nutritional status which is a powerful predictor 
of mortality. As it is not clear how well nutritional markers used in the clinical care of 
these patients accurately reflect nutritional status we evaluated in post-hoc, cross-
sectional observational studies several common markers of malnutrition and PEW, 
and assessed their correlations to each other and to survival in patients with CKD 
stage 5 (CKD 5). 
In Study I self-rated appetite along with anthropometrics and biochemical markers of 
nutritional status were measured and related to all-cause mortality in 523 CKD 5 
patients. This study shows that self-rated appetite is not an independent predictor of 
survival in most patients with CKD 5. 
In Study II serum albumin, and other biochemical markers of nutritional status, clinical 
anthropometrics, and dual-energy x-ray absorptiometry, were assessed in CKD 5 
patients. Analyzing data from 458 incident and 383 prevalent dialysis patients, we 
found that serum albumin correlates poorly with other markers of nutritional status. 
Thus, its value as a reliable marker of nutritional status appears limited. 
In Study III serum insulin-like growth factor (IGF)-1 and biochemical, clinical, and 
densitometric markers of nutritional status and mineral and bone metabolism were 
evaluated in 365 incident dialysis patients. This study shows that low serum IGF-1 
associates with a sarcopenic body composition and with markers of disturbed bone 
metabolism, while also predicting an increased risk of mortality. 
In Study IV we assessed temporal changes in the appetite regulating peptide 
hormones pancreatic polypeptide (PP), glucose-dependent insulinotropic polypeptide 
(GIP), and glucagon-like peptide 1 (GLP-1) following a fat- and carbohydrate-rich meal 
in 6 hemodialysis patients and 9 healthy controls. This study shows that fasting levels 
of both PP and GIP levels and the postprandial PP response are elevated in HD 
patients as compared to controls. We speculate that this may be one mechanism 
whereby CKD engenders poor appetite. 
 
  
In Study V several common markers of nutritional status were analyzed in 399 
incident dialysis patients and 289 prevalent dialysis patients and, using multivariate 
regression models, related to results of subjective global assessment (SGA). This study 
shows that serum levels of albumin, creatinine, and cholesterol as well as handgrip 
strength are in general only weakly or not at all associated with PEW as assessed by 
SGA following correction for cofounders. 
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1 THESIS SUMMARY 
Both malnutrition (defined as a state of nutrient deficiency secondary to diet patterns) 
and protein-energy wasting (defined as a state of body protein catabolism and 
insufficient energy intake secondary to chronic renal disease), usually occurring 
together in chronic kidney disease and here used as interchangeable entities, are 
common in chronic kidney disease patients, where they also are strongly associated 
with low-grade inflammation and an adverse outcome (1-7). The main goal of this 
thesis was to investigate the relative usefulness of clinically available tools to 
accurately identify and monitor protein-energy wasting and malnutrition in chronic 
kidney disease as identifying patients at risk is a goal in itself and also a prerequisite 
for interventional therapies and prioritization of resources. By studying a broad 
spectrum of renal diseases of patients with reduced glomerular filtration rates but not 
yet on dialysis, as well as patients on both hemodialysis and peritoneal dialysis, we 
increase the practical applicability of our results in the clinical setting. Unfortunately, 
our data do not support the use of any one single marker for the unequivocal 
identification of malnourished chronic kidney disease patients, and even less makes it 
likely that commonly used methods can be clinically useful for risk stratification. 
Instead the results of our studies suggest that a panel combining several markers and 
including ideally also subjective global assessment should be used if possible. Thus, 
further studies are urgently needed to identify and validate better and more reliable 
tools to assess and monitor nutritional status in various chronic kidney disease 
populations.  
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2 INTRODUCTION 
2.1 CHRONIC KIDNEY DISEASE  
Chronic kidney disease (CKD), often leading to a gradual and irreparable loss of renal 
function, is common enough to be considered a worldwide public health threat (8). In 
the United States alone, 14.5% of adults are likely to have some degree of CKD (9). A 
similar prevalence has been reported in Europe, Australia and Asia (9-11). Having 
multiple etiologies, CKD is defined as a state of kidney damage and/or decreased 
glomerular filtration that lasts for at least 3 months (8). Long relatively unnoticed, the 
worldwide trend of increasing body weight, hypertension and insulin resistance in the 
population has been followed by a similar but delayed increase in CKD prevalence 
(12). This increase has also led to an increased awareness, and a common 
nomenclature developed to facilitate clinical and scientific evaluation. According to 
this, CKD can be divided into 5 stages (Table 1) depending on the presence of kidney 
damage, i.e., albuminuria, and loss of kidney function as assessed by glomerular 
filtration rate (GFR). CKD is usually characterized by a progressive course of worsening 
renal function eventually leading to stage 5 CKD, also called end-stage renal disease 
(ESRD), which requires renal replacement therapy (RRT). Currently, two major kinds of 
RRT are clinically available, dialysis and kidney transplantation. Dialysis is furthermore 
available as hemodialysis (HD, entailing extracorporeal filtration of blood) or 
peritoneal dialysis (PD, which utilises the peritoneal membrane as a filter).  
 
Table 1. Classification of CKD according to KDIGO guidelines (8). 
Prevalence 
of CKD* 
Stage Description GFR 
(mL/min/1.73m2) 
3.1% CKD 1 Kidney damage with normal GFR ≥90 
4.1% CKD 2 Kidney damage with mildly decreased 
GFR 
60-89 
7.6% CKD 3 Moderate decrease in GFR 30-59 
0.25% CKD 4 Severe decrease in GFR 15-29 
0.25% CKD 5 Kidney failure <15 or dialysis 
*Prevalence of CKD in the American population (13)  
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2.2 Renal replacement therapy 
While a kidney transplant is the preferred option of RRT, the limited availability of 
organs and the risks of the operative procedure mean that most patients that reach 
CKD 5 are started on dialysis. While renal transplantation is by far the best method of 
RRT, fully replacing kidneys in case of a well-functioning graft, dialysis has its 
drawbacks and limitations. Both the dialyzer membrane used for HD and the 
peritoneal membrane used for PD are less selective than the kidney’s glomerular 
filtration barrier. Therefore, many essential nutrients are lost into the dialysate and 
the dialysis procedure may cause an inflammatory response stimulating protein 
catabolism. Nevertheless, dialysis has the capability of improving several indices of 
nutritional status. 
2.3 How CKD alters nutritional status 
Patients with CKD present a variety of metabolic and nutritional abnormalities (14-16). 
An early diagnosis and proper treatment of these conditions, including dietary 
interventions, can slow down the progression of disease symptoms (17) and may also 
ameliorate disease complications such as hyperkalemia, acidosis and sarcopenia (18). 
Metabolic and nutritional abnormalities arise in CKD from both pathophysiological 
(e.g. uremic toxicity, altered metabolism) and iatrogenic (e.g. polypharmacy and the 
prescription of a low protein diets to slow disease progression) causes. Patients with 
renal disease are also more vulnerable to malnutrition due to their intake of 
numerous medications, a more restrictive diet, disabilities and disease-related social 
issues. With the start of dialysis, some of these abnormalities are improved, but 
others remain or worsen, while new factors also likely contribute to increase the 
prevalence of malnutrition and protein-energy wasting (PEW) in this population (19).  
2.4 Malnutrition versus PEW 
Over the years, many different nomenclatures have developed to describe the various 
nutritional disturbances seen in patients with CKD. This can lead to confusion and 
misunderstandings (20). In the following, I will use the terms malnutrition and PEW as 
outlined below and in Table 2. 
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Malnutrition in the context of CKD occurs when an inappropriate dietary intake of one 
or more macro- or micro-nutrients results due to an inadequate diet. Meanwhile, 
wasting is the result of metabolic abnormalities that cannot be corrected solely by an 
improved diet (21). Thus, malnutrition may indicate both a state of under-nutrition 
and one of energy excess (22, 23). For instance, malnutrition may be diagnosed both 
in a sarcopenic dialysis patient with a too low calorie intake, as well as in an obese 
insulin-resistant patient with CKD stage 3 and a very high energy intake.  
 
PEW is meanwhile defined as a state of gradual and non-functional loss of muscle and 
fat tissue, eventually resulting in cachexia (19, 20). In addition, decreased functional 
capacity due to metabolic stresses is often present. Also, the described state is not 
merely caused by an inadequate dietary intake, but rather the result of disease 
processes such as acidosis (24, 25), inflammation-driven catabolism (26), nutrient 
losses in the dialysate (27, 28), along with  endocrine disturbances, such as 
hyperparathyroidism (29), hyper-glucagonemia (30) and peripheral insulin resistance 
(31). PEW is currently the recommended term to describe the commonly observed 
alterations of nutritional status seen with CKD (20) although the term malnutrition is 
still widely used. PEW may be seen as a broader concept that includes also 
malnutrition; in reality, both PEW and “pure” malnutrition are usually present in CKD 
patients with poor nutritional status. 
Further differentiating the two syndromes, PEW is but mostly caused by alterations in 
physiological processes such as energy expenditure, inflammation, central nervous 
system (CNS) signaling and endocrine disorders, resulting in inappropriate catabolism 
of muscle more than of fat (19, 20, 32).  Further complicating the picture, a low 
protein diet is advocated for many CKD stage 4 and 5 subjects, as it has been 
demonstrated to reduce uremic symptoms and to slow the rate of renal function 
decline (20). However, a low protein diet may also result in a negative protein balance, 
especially in subjects not taking amino acid and/or keto acid supplementation. 
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Table 2. Differences between malnutrition and PEW. 
2.5 Prevalence of malnutrition/PEW in different CKD populations 
In scientific studies, the prevalence of malnutrition, defined differently between 
studies, in early to moderate CKD is usually lower, while as CKD advances it increases 
dramatically in prevalent dialysis patients (14-16, 20). Furthermore, transplanted 
patients (T) often improve their nutritional status and ameliorate PEW symptoms.  
Table 3. Shows a number of studies describing the prevalence of PEW in several 
patients groups from several countries.  
 
 
 
 
 
 
 
 Context Clinical signs Biochemical 
signs 
Treatment 
response 
Malnutrition Occurs when 
insufficient dietary 
intake results from 
an inadequate diet, 
leading to a scarcity 
of one or more 
nutrients. 
Associated with 
the degree of 
uremic 
symptoms. 
Food intake low. 
Energy 
expenditure low-
normal. 
Preferential loss 
of fat over lean 
body mass.  
 
Normal or low 
s-albumin 
 
Reversed by 
adequate dialysis 
and nutritional 
support 
 
PEW A state of loss of 
muscle and fat 
tissues together 
with metabolic 
changes not 
amenable to dietary 
intervention in the 
context of CKD. 
Associated with 
degree of co-
morbidities and 
inflammation.  
Increased energy 
expenditure. 
Fat is 
underutilized - 
muscle is wasted 
 
Markedly low 
s-albumin, 
pre-albumin, 
s-creatinine 
High CRP 
 
Correction of 
acidosis, 
inflammation, 
nutritional 
interventions, 
adequate, dialysis 
doses 
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Table 3. Shows a number of studies describing the prevalence of PEW in several 
patients groups from several countries. BMI, body mass index; LBM, lean body mass; MIS, 
malnutrition inflammation score; nPNA, normalized protein nitrogen appearance and SGA, subjective 
global assessment; T, transplanted patients. 
2.6 Linking PEW and malnutrition to outcomes 
Decreased indices of nutritional status have been associated with increased risk of 
death (44). Indeed, decreased muscle mass and low protein and energy intakes are 
linked to worse outcome (44). The importance of PEW as a determinant of poor 
outcome in CKD population is reflected by the ‘reverse epidemiology phenomenon’. 
For example, in patients with late stage CKD, low (rather than high) cholesterol and 
low (rather than high) BMI, predict poor outcome (45). By contrast, in the general 
population those with hypercholesterolemia and obesity have an increased risk of co-
morbidities and mortality.  
As obesity is rapidly growing in the general population (and is one risk factor for 
kidney disease), it is not surprising that many CKD patients are overweight or obese. 
Indeed, obesity is a risk factor for CKD progression (46).  
Study  Year  Country  Sample size  Age  Method  Prevalence  
Chruściel et al. (33) 2001 Poland 109 T 40±11 SGA 
BMI< 21 
21% 
23.3% 
Djukanović et al. (34) 2003 Yugoslavia 452 T 
 
13-54 y BMI <21 
 
15% 
Vasselai et al. (35) 2008  Brazil  45 PD  53±15  SGA  35.6%  
Sanches et al. (36) 2008 Brazil 122 CKD 3-4 55 ± 11 SGA 18% 
Campbell et al. (37) 2008 Australia 56  CKD 3-4 70±14 SGA 12% 
de Mutsert et al. (38) 2009  Netherlands  1601 dialysis  59±15  SGA  28%  
Cordeiro et al. (39) 2009  Sweden  173 HD  65(51-74)  SGA  43%  
Rambod et al. (40) 2009  USA  809 HD  53±15  MIS>5  46.8  
Szeto et al.(41)  2010  China  314 PD  60±12  MIS>6  
SGA  
60.2%  
28.7%  
Miyamoto et al. (42) 2011  Sweden  280 dialysis  56(35-68)  SGA  30.3%  
Leinig et al. (43) 2011  Brazil  199 PD  57±13  SGA  64.7%  
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Despite weight status, PEW is equally harmful in obese as it is in lean CKD patients 
(47). Although many possible explanations have been proposed for these 
contradictory associations, the most convincing one is that PEW, a risk factor for 
increased mortality, associates with a decrease in cholesterol and BMI in these 
patients. Obviously, to prevent, diagnose – as soon as it develops -and treat PEW 
effectively in CKD subjects must be a priority. 
2.7 Causes of malnutrition and PEW in CKD  
2.7.1 Renal causes of malnutrition and PEW 
The kidneys are central to various metabolic processes, including the recycling of 
amino-acids from small circulating peptides, the re-uptake of glucose and the 
metabolism of waste products from the urea cycle. As renal function decreases, the 
accumulation of waste compounds occurs, resulting in a toxic concentration of 
potentially harmful substances. This state of uremic intoxication, also known as 
uremia, is both detrimental to systemic homeostasis and has detrimental 
consequences for more complex metabolic processes such as appetite regulation and 
food intake (48, 49) (Figure 1).  
2.7.2 Chronic low-grade inflammation 
While malnutrition is doubtlessly an important cause of PEW in CKD, much research 
demonstrate chronic low-grade inflammation as a causal factor of equal importance 
(32). It has been reported that  inflammation is present in 30 to 50% of ESRD patients 
(50); furthermore, inflammation is an important cause of hypoalbuminaemia (51), 
which is a risk factor for mortality in these patients (52-55). Inflammation has been 
shown to decrease protein production and to increase protein breakdown, resulting in 
a highly negative protein balance (56). Indeed, Stenvinkel et al. found  markedly higher 
prevalence of inflammation in patients with cardiovascular disease (CVD) and 
malnutrition terming this commonly observed triad of concurrent complications as 
malnutrition, inflammation and arteriosclerosis (MIA) syndrome (1, 50), and others 
have made similar observations (3).   
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2.7.3 Metabolic acidosis  
Metabolic acidosis is a common metabolic disturbance in CKD patients that 
predispose to bone disease, altered protein metabolism, skeletal muscle wasting, and 
progressive glomerular filtration rate loss (57). In addition, acidosis induces increased 
protein catabolism with degradation of the essential, branched-chain amino acids and 
muscle protein (58). Moreover, metabolic acidosis is also known to suppress synthesis 
of proteins such as albumin (58), and, as noted above low levels of albumin as well as 
catabolism are strong predictors of mortality.  Indeed, metabolic acidosis, generally 
manifested by reduced serum bicarbonate levels, is also correlated with increased 
mortality (59, 60). Interestingly, Kovesdy et al. found that not only low levels of 
bicarbonate (<22 mmol/L) are associated with mortality, but also high levels (>29 
mmol/L) (61).  
2.7.4 Co-morbidities 
Like many other diseases associated with aging and unhealthy living, CKD rarely occurs 
in isolation but rather is often accompanied by various co-morbid conditions. Indeed,  
as many as 86% of patients with CKD may have at least one co-morbidity (62). CKD is 
often the end-result of diet-related diseases such as diabetes, hypertension, and 
atherosclerosis. In fact, diabetes which is now the leading cause of CKD and ESRD in 
many countries including the US (63) may also increase the risk of PEW. Indeed, Pupim 
et al. reported that diabetic ESRD patients are more likely to develop PEW than non-
diabetic patients, as the diabetic patients had a greater skeletal muscle protein loss 
(64). In addition, hypertension is the second main cause of development of CKD (65) 
and the majority of patients with stage 4–5 CKD have high blood pressure. Moreover, 
cardiovascular disease (CVD) is present in a large proportion of CKD patients (65). In 
these patients, both diabetes and hypertension are associated with CKD progression 
and cardiovascular death (66). These and several other disturbances predispose CKD 
patients to deteriorations of nutritional status and development of PEW. 
2.7.5 Medications 
Often CKD patients have multiple medication requirements and need to comply with 
intense dialysis sessions and often strict dietary recommendations. In addition, these 
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patients commonly need to take numerous medications to treat other existing co-
morbidities (67). The interactions of these drugs can alter taste or may interact with 
nutrient metabolism, which increases the risk of malnutrition.  
2.7.6 Dialysis treatment 
Dialysis treatment has undoubtedly prolonged CKD patients´ lifespan and improved 
uremic intoxication commonly found in pre-dialysis patients. However, these 
benefits come with potential side-effects.  
A detailed review of the literature (68) have shown that PD therapy induces a 
decreased turnover rates and a reduced efficiency of protein turnover. This 
condition is especially harmful under stress as nutrient intake may be insufficient 
especially during superimposed catabolic illnesses (68). In HD patients, many factors 
that influence protein metabolism predispose these patients to increased catabolism 
and loss of lean body mass. It has been shown that the HD procedure in itself can 
induce protein catabolism – these adverse effects are likely the result of decreased 
protein production and increased protein breakdown (69, 70). Indeed, low plasma 
amino acid levels during HD sessions are thought to be one of the possible 
explanations for increased catabolism (70). 
2.7.7 Loss of appetite  
Loss of appetite, or anorexia, often results in an insufficient intake of nutrients, and is 
common in CKD where it significantly contributes to malnutrition (72). Anorexia 
commonly occurs when the GFR is less than 10%-15% of normal (20), with a reported 
prevalence of 35-50% in diverse populations of CKD patients (73-75). In addition, older 
kidney patients may face an extra obstacle to a healthy and well-balanced diet, if they 
suffer from odontological problems. It is not uncommon for these patients to suffer 
from dental problems such as higher number of decayed, missing or filled teeth (76) 
and an increased prevalence of periodontitis (77). These issues can evolve into 
chewing and/or biting problems, making patients less likely to consume high-fiber 
foods such as bread, fruits or vegetables and therefore risking their essential nutrient 
intake. 
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Figure 1. Multifactorial causes of PEW. 
 
 
As CKD progresses, anorexia develops gradually (78). The exact mechanisms remain 
unclear, but are thought to involve uremic intoxication, inflammation and hormonal 
derangements. Among the hormonal changes described are both increases in 
circulating levels of anorexigens such as leptin, as well as decreases in orexigens such 
as ghrelin (79). Finally, as patients progress to ESRD and dialysis is introduced, an 
improvement in appetite is often seen (49).  
2.7.8 Social aspects  
Social aspects related to CKD also contribute to a worse nutritional status. The burden 
of living with kidney disease is aggravated when emotional problems such as 
depression, cognitive impairments and social isolation occur. It has been shown that 
depressive behavior and depression in CKD patients is closely linked to the presence of 
PEW (80). In fact, dialysis patients with poor appetite have been reported to be more 
often depressed (73). Furthermore, social factors associated with aging and chronic 
disease, such as loneliness and poverty, are all highly prevalent in CKD patients (20) 
and likely contribute to malnutrition and PEW. 
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2.8 Assessment of PEW in CKD patients 
2.8.1 Historical background 
While consensus exists as to the importance of identifying and treating malnourished 
CKD patients (81, 82), the necessary tools for such intervention are currently lacking. 
Over the years, many methods have been proposed to identify malnourished and 
wasted CKD patients, as well as to grade the severity of their state (15, 83-92). 
Unfortunately, none has proven both easy to use in the clinical setting, easy to 
interpret and accurately linked to patient outcomes and composite nutritional status. 
Thus, there is currently no single tool that can be used to identify high-risk individuals; 
with so many concurrent metabolic and nutritional abnormalities, such a tool has 
remained elusive. The National Kidney Foundation Clinical Practice Guidelines for 
Nutrition in Chronic Renal failure (93) thus, recommends that nutritional status should 
not be evaluated with only a single measure alone, but instead using a combination of 
valid, complementary measures. Indeed, according to an expert panel directed by the 
International Society of Renal Nutrition and Metabolism (20) the current   
recommended procedure to diagnose PEW requires the analysis of serum chemistry 
(s-albumin, s-prealbumin and s-cholesterol), body mass (assessed by BMI, weight 
variation and percent of body fat), signs of muscle wasting overtime (reduced mid-
arm muscle circumference and creatinine appearance) as well as unintentional low 
dietary intake (for at least 2 months).  
These measures may include biological assessment of protein-energy status, 
subjective global assessment, dietary intake assessment and anthropometry 
measurements. However, the ideal way to measure PEW not always corresponds to 
the hectic reality in daily clinical practice. Therefore, SGA has been used as a surrogate 
of PEW in many studies (38, 94, 95) 
2.8.2 Biomarkers of nutritional status 
Biochemical parameters are normally used to assess and monitor nutritional status in 
CKD patients. However, none of the currently favored biomarkers have been 
demonstrated to accurately reflect nutritional status in CKD (1, 53, 96). Instead, strong 
associations between several biomarkers and mortality seem to derive, at least in 
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part, from their close association with inflammation (2), and in part from the 
important role of the kidney in metabolizing circulating peptides (97). 
2.8.2.1 Serum albumin 
The amount of serum albumin is determined by its synthesis, breakdown and volume 
of distribution (98). In CKD patients, factors such as overhydration, proteinuria and 
losses into the dialysate and urine may cause a decrease in plasma protein 
concentration. Counter-regulatory mechanisms may also influence the serum albumin 
concentration. Whereas in the short term, protein deficiency decreases the rate of 
albumin synthesis (99), compensation in the long term may occur through a decrease 
in albumin breakdown and a shift of albumin from the extravascular to the 
intravascular space. Additionally, albumin has a relatively long half-life and is present 
in large quantities (100), limiting the impact of a decreased protein intake on 
concentrations of albumin. Even in some extreme cases of malnutrition, such as 
marasmus, serum albumin levels in these patients remain normal (101). In 
kwashiorkor, on the contrary, serum albumin levels are usually low (102, 103). 
However, it is important to keep in mind that kwashiorkor is typically accompanied by 
infections and severe protein intake deficiency (86, 104). In a study by Kaysen et al. 
(105) low serum albumin levels in dialysis patients were mainly associated with  
inflammation. Thus, it seems that hypoalbuminemia in CKD patients is rather 
associated with a chronic inflammatory state than insufficient food intake (106). 
Despite the prevailing acceptance of albumin as a nutritional status biomarker in CKD, 
circulating levels of albumin are in fact - as will be shown in Study II in this thesis - not 
an appropriate accurate indicator of nutritional status (107).    
2.8.2.2 Serum creatinine  
Creatinine is the breakdown product of creatine phosphate in muscle. Under  stable 
kidney function, creatinine is typically produced at a relatively regular rate by the body 
depending on the total amount of muscle mass (108). Low lean muscle mass has been 
associated with increased risk of mortality in CKD and dialysis patients (71, 109). Lean 
muscle mass in these patients is commonly assessed by the serum creatinine level due 
to its easy availability, cost-effectiveness and reliability nature (110).  
   13 
2.8.2.3 Insulin-like growth factor-1 (IGF-1) and binding proteins  
IGF-I is a peptide hormone, produced predominantly by the liver in response to 
pituitary GH (growth hormone), which is involved in a number of physiological 
processes. The production of IGF-I signals the availability of nutrients needed for its 
anabolic actions. IGF-I has a considerably short long half-life of only 2 to 6 hours and is 
regulated by nutrition and dysregulated in states of under- and over-nutrition, its 
serum concentrations falling in malnutrition and responding promptly to re-feeding 
(111). Therefore, its usefulness as nutritional biomarker has been proposed (112). 
Compared to other commonly used markers of nutritional status, such as serum 
albumin and serum transferrin, IGF-1 was found to correlate better with 
anthropometric measurements markers of nutritional status in HD patients (113). 
However, due to its high cost, the use of IGF-1 is limited in the research setting while 
its high costs definitely is a barrier for its use in clinical practice (114). In Study III we 
found that IGF-1 levels correlated with several markers of body composition and 
nutritional status, and with mortality. 
2.8.2.4 C-reactive protein (CRP) 
CRP is a marker of inflammation - not a direct nutritional marker (114). However, it 
has an important function in the overall assessment of nutritional status in CKD 
patients as it is an acute phase reactant that inversely correlates with the 
concentrations of visceral proteins (115). In practice, one should remember that very 
low levels of visceral proteins, for instance serum albumin, are often due to presence 
of inflammation rather than low protein intake or protein depletion (114). Thus, both 
in the clinical and research setting it is recommended to check CRP levels in 
conjunction with other nutritional markers and make a decision for possible 
nutritional intervention, as well as intervention against factors causing CRP to rise.  
2.8.2.5 Cholesterol 
Cholesterol is a lipoprotein that functions as a precursor for the synthesis of steroid 
hormones, bile acids, and vitamin D.  Serum cholesterol (and several other blood lipids 
and lipoproteins; such as, total cholesterol, LDL cholesterol, HDL cholesterol and 
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triglycerides) are indicators of patients´ nutritional status. Indeed, s-cholesterol has 
been proposed as assessment criterion for malnutrition and PEW (20).   
Contrary to the general population (116), a high s-cholesterol level in the CKD and 
dialysis population is associated with improved survival (3, 117). However, this 
association seems to only be true in patients who are inflamed and/or malnourished 
(118, 119), which suggest that low levels of s-cholesterol may be a surrogate marker 
of inflammation and/or malnutrition.    
2.8.3 Clinical and anthropometric markers of nutritional status 
2.8.3.1 Subjective global assessment (SGA) 
 With limited value of serum albumin and other circulating surrogate biomarkers of 
nutritional status, subjective global assessment (SGA) (120) has been proposed as an 
easy, inexpensive, and handy subjective method of assessing nutritional status in CKD 
patients. SGA is currently considered to be a reliable marker of malnutrition and PEW 
in uremic patients (93, 121). Additionally, SGA uses scoring of a patient´s medical 
history and physical status as revealed by physical examination to distinguish well-
nourished, mildly malnourished and severely malnourished patients (or using finer 
grading). The attributes scored in the SGA assessment include the following: 
gastrointestinal symptoms, dietary intake, body weight, disease state and functional 
capacity.  Due to its strong correlations with PEW (122) and outcomes (123), SGA is 
recommended as a component of longitudinal monitoring of chronic dialysis patients 
by, amongst others, the National Kidney Foundation Kidney Disease/Dialysis 
Outcomes and Quality Initiative (K/DOQI) (93).   
Although several studies show that SGA is a useful tool in CKD (83) (84), it should be 
kept in mind that SGA is still a subjective score that may be biased by inter- and intra-
personal differences. As such, it is perhaps best employed in a longitudinal manner by 
the same trained investigator to follow patients over time.   
2.8.3.2 Malnutrition inflammation score (MIS) 
As inflammation is closely related with nutritional status and PEW in CKD patients, the 
MIS (124) scoring system was developed in order to better assess this complex 
syndrome. Therefore, by using components from the SGA questionnaire (weight 
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change, dietary intake, GI symptoms, functional capacity, co-morbidity, subcutaneous 
fat, and signs of muscle wasting), as well as adding biochemical parameters that are 
influenced by inflammation status (s-albumin and total iron-binding capacity, TIBC) 
and body mass index (BMI). In total, there are 10 parameters in the MIS, each 
including four degrees of severity (where 0 = normal and 3= severely abnormal) and 
adding each one of the MIS components to have the final score (0= normal nutritional 
status and 30 = severely malnourished) (124). 
2.8.3.3 Other nutritional scoring systems  
In addition to SGA and MIS, alternative scoring systems to assess nutritional status 
have been developed. Among those, Mini Nutritional Assessment (MNA) (125) and  
Mini-Nutritional Assessment–Short Form (MNA-SF) (126) have been developed as 
nutritional assessment tools for the geriatric population. In addition, these tools have 
also been used in CKD and dialysis patients (125, 127); however, the usefulness of the 
MNA-SF is still questionable (128) 
2.8.3.4 Dietary records 
As previously discussed, insufficient food intake associates with malnutrition and the 
development of PEW (19). Therefore, it is of paramount importance to assess dietary 
intake in CKD patients. Many methods have been used throughout the years in an 
attempt to estimate dietary intake; the methods described below are the most 
commonly used in clinical and research practice. 
Food diary consists of carefully written records of food and beverage intake as well as 
the amount consumed during each meal and snacks (129). It is recommended that the 
recording is done after each eating occasion in order to avoid memory bias. In 
addition, food diaries are usually kept for seven consecutive days or three non-
consecutive days (for example, two week days and one day during weekend), as to 
have a more representative sample of patient´s diet.  
24-Hour dietary recall usually consists of an interview where the patient is asked to 
recall the previous 24-hours food and beverage intakes (including the amount and 
time of consumption) (129). In addition, the success of these interviews relies to a 
large extent on the experience of the interviewer who ideally should be a dietitian or a 
health care worker trained to perform such tasks.    
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Food frequency questionnaire (FFQ) consists of a list of foods (depending on the 
nutrients or foods of interest) with selection of options relating to the frequency of 
consumption of each of the foods listed (for example, times per day, daily, weekly, or 
monthly) (130). Furthermore, FFQs inquire about dietary intake given within a 
specified time frame (such as, the past month, 6 months or 1 year). This questionnaire 
was elaborated to collect dietary information from large sample of individuals. It is 
usually self-administered, but sometimes an interviewer can administer in person or 
through telephone interview (131).  
The dietary records described above are usually used as a proxy for dietary intake; all 
of the currently used dietary records suffer from a number of limitations. First, these 
methods are by nature subjective and very much dependent on patient´s memory and 
willingness to cooperate. Second, patients are very likely to underreport foods that 
are considered unhealthy and overreport those that are recommended (132). Third, in 
general these methods contain a great amount of measurement errors which can 
make the data collected unreliable (133, 134).  Therefore, one should be aware that 
assessing one´s diet is a difficult task as objective tools to collect information about 
food and beverage intake remains to be created.   
Protein intake can be estimated also by more objective means using equations that 
relate total nitrogen losses to dietary protein intake assuming steady state. In non-
dialyzed CKD patients and PD patients, collection of 24-h urine (and in PD patients also 
dialysate) and measurement of urea in removed fluids and in plasma allow calculation 
of the protein equivalent of nitrogen appearance (PNA) providing an estimate of 
dietary protein intake.  In HD patients, assessment of PNA using urea kinetic modeling 
can be performed without actually measuring urea removal. 
2.8.3.5 Body composition 
Theoretically, body composition and the contents of fat, protein and water should 
reflect long-term dietary intake and PEW. Over time, and also depending on the 
severity of the disease, changes in body composition are inevitable especially in CKD 
patients in whom body composition can change more rapidly than in healthy older 
adults. CKD affects how the body metabolizes fat, keeps water balance, and is able to 
maintain muscle, bone and other components of lean body mass. While several 
methods have been employed in assessing body composition in CKD patients, these 
   17 
evaluations need to standardized and validated in these patients – as they can suffer 
from the large variation of body composition overtime. 
2.8.3.6 Anthropometrics 
Anthropometric measurements such as body weight and height (and BMI, see below) 
should as a rule always be included when assessing nutritional status. Skin fold 
thickness is a more specific anthropometric tool widely used in the clinical practice 
due to its low cost, simplicity and non-invasive nature. It is used to estimate both fat 
mass and fat-free mass (135). In combination with measurement of mid-arm 
circumference one can also calculate mid-arm muscle circumference which is a 
surrogate marker of lean body mass. However, skin fold thickness measurements 
suffer from a large intra- and inter-observer variability, and are only modestly reliable 
(136).  
Another marker used to determine body fat mass is waist circumference. This is again 
a simple and easy method, which has been suggested to predict survival in CKD 
patients (137). However, as fat mass does not necessarily reflect PEW in CKD, waist 
circumference is likely not a good marker of the nutritional deficiencies associated 
with PEW. 
2.8.3.7 Body mass index (BMI) 
BMI is calculated as body weight in kilograms divided by the square of height in 
meters. According to the World Health Organization (WHO) guidelines, obesity is 
defined as a BMI ≥30.0 kg/m2, and overweight as a BMI of ≥25.0 kg/m2. Normal 
weight is defined as a BMI of 18.5–24.9 kg/m2, which is within the normal range 
according to the WHO, and underweight as a BMI <18.5 kg/m2. In CKD patients, BMI 
may not reflect real nutritional status, as gross imbalance in fluid status in these 
patients may cloud the results. Also, loss of muscle mass is characteristic in PEW; 
however, a relatively well-preserved fat mass still usually remain, resulting in small 
changes in BMI that can be disguised by imbalances in fluid homeostasis (47). Finally, 
overweight ESRD patients may also suffer from PEW (47). For these reasons, BMI 
alone does not accurately reflect nutritional status or PEW in CKD patients. 
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2.8.3.8 Hand grip strength (HGS) 
Muscle strength in CKD patients is often evaluated by muscle dynamometry such as 
hand grip strength (HGS) which associates with lean body mass as assessed by 
anthropometry, dual-energy X-ray absorptiometry (DEXA, see below) and creatinine 
kinetics and with nutritional status as assessed by SGA score. In addition, the 
combined assessment of body composition (lean body mass) and muscle function has 
begun to become more prevalent as composite marker of nutritional status (138). 
Indeed, a dynamometric HGS measurement standardized to age and gender has 
emerged as an easily performed bedside test (139) that is considered to be a reliable 
and useful marker of both nutritional status and future mortality risk (1, 92).  
2.8.4 Other methods to assess nutritional status 
2.8.4.1 Bioelectrical impedance and conductance  
Bioelectrical impedance analysis (BIA) has been proposed as a noninvasive and simple 
technique to measure body hydration status of patients, especially as regards the 
determination of “dry” body weight in HD patients (140). Also, BIA has also been 
suggested as a valuable tool in subjects undergoing PD (141). BIA is based on the 
assumption that human body may be viewed as a number of parallel connected 
resistors. By connecting electrodes to various body parts (typically arms and legs) with 
a conductive gel, electrical current passes through the body at various frequencies and 
then the conductance is measured. Current standard BIA models used in CKD view the 
body as 5 interconnecting cylinders, 2 for the arms, 2 for the legs, and 1 for the trunk, 
instead of the more common assumption previously that the whole body can be seen 
as just one cylinder. BIA models are prone to errors of simplification which depend on 
body size, shape and regional fluid accumulation.  
2.8.4.2 Dual-energy x-ray absorptiometry 
A more reliable tool to estimate body composition is dual energy X-ray 
absorptiometry (DEXA). DEXA passes low-energy x-rays through the body to measure 
fat mass, fat-free mass and bone mineral density (142). While DEXA is relatively good 
at measuring fat mass (136), it is not used routinely in the clinical setting due to its 
high cost and its inaccuracy in severely overhydrated patients (143). Furthermore, the 
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amount of radiation, although small, may be a concern in patients exposed to DEXA 
repeatedly over many years. 
2.8.4.3 Other methods 
There are also several specialized methods that can be used to assess nutritional 
status in clinical research such as ultrasonography, magnetic resonance imaging, 
computed tomography and total body potassium and total body nitrogen but these 
methods are used less often and usually serve as tools for validation of more common 
markers.  
2.9 Studies on prevention and treatment PEW  
Throughout this thesis, we discussed the fatal consequences of PEW and poor 
nutritional status; thus, the importance of assessing and monitoring it. In this session, 
we will discuss the current available therapies used to prevent and treat PEW.  
2.9.1 Treatment of co-morbidities 
Interventions that target common co-morbidities such as CVD, diabetes and infections 
are of utmost importance in the prevention and treatment of PEW in CKD patients. In 
addition, underlying disturbances linked to uremia such as metabolic acidosis, fluid 
retention and inflammation to name a few are helpful in reducing catabolism and 
thereby resolve to some extension PEW and malnutrition. Indeed, when reduced 
serum bicarbonate is corrected, it has been shown to improve nutrition status and 
slow progression toward ESRD (18). Among measures to alleviate inflammation, 
nutritional supplementation with ω-3 fatty acid has shown the potential to improve 
systemic inflammation and has been tested in several intervention studies involving 
HD patients, resulting in improved outcomes (144, 145)  
In addition, treatment of co-morbidities, in CKD patients, helps prevent progression of 
CKD to dialysis or renal transplantation, cardiovascular events and premature death. 
Since cardiovascular death is overrepresented in this population (146), treatment of 
cardiovascular risk factors must be a priority. For example, appropriate management 
of diabetes and control of blood pressure are highly advisable (147), as well as 
treatment of hyperlipidemia and reduction of proteinuria (147) 
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2.9.2 Early nutritional intervention  
Initiatives to improve food intake in CKD patients are of paramount importance. In 
addition, in order to compensate for nutrient losses during dialysis and to further 
improve nutritional status of dialysis patients, intradialytic nutritional support has 
been developed. Apart from the nutritional support, these interventions take the form 
of intravenous (in HD) and intra-peritoneal (in PD) infusions. Intra-dialytic parenteral 
nutrition (IDPN) is an acknowledged method of protein and energy supplementation 
in HD patients. Typically composed of a mixture of amino acids, dextrose and lipids, 
IDPN has been shown to increase protein synthesis, decrease protein degradation, 
resulting in a highly positive protein balance (148). However, recent studies have 
demonstrated no additional benefit of IDPN over oral nutritional support (149). 
Therefore, current guidelines limit the use of IDPN to wasted subjects in whom oral 
nutritional support turned out to be ineffective in improving nutritional status (150). 
Nutritional counseling is a mainstay of therapy, with the initial goal of protein 
restriction in pre-dialysis CKD patients while because of the catabolic influence of the 
dialysis procedure switching to increasing protein and calorie intake as dialysis is 
started (150). In the research setting, appetite stimulation (151) has proven to be 
effective for short periods, but these methods are seldom tried in the clinic. For 
example, subcutaneous ghrelin and the administration of melanocortin-receptor 
antagonists have both been reported to reduce uremic anorexia and lead to increased 
food intake (152, 153) . On the other hand, administration of nutritional supplements 
(154)  as well as daily dialysis sessions (155) are increasingly used in the clinic. In Table 
4, we discuss some nutritional intervention studies aiming to improve nutritional 
parameters in randomized trials in patients HD and PD patients.    
 
Table 4. Randomized nutritional interventions to improve nutritional status in HD and 
PD patients*. Adapted from (81).  
Study Intervention  
 
Patients  (n) Results  
Eustace et al.  
(2000)(156) 
EAA (3.6 g with meals  
three-times daily) vs 
placebo  
for 3 months 
HD/PD (47) 
Albumin  
concentration  
≤38 g/l 
S-albumin levels in HD patients (EAA vs 
placebo) ⬆ by 2.2 g/l 
Improvement in HGS  and SF-12®  
Correlation between baseline CRP levels 
and improvement in albumin levels. 
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Gonzalez-
Espinoza et al 
(2005)(157) 
Egg albumin-based 
ONS;  
open-label controlled 
trial  
with 6-month follow-
up 
PD (28) 
Case (13) 
Control (15) 
S-albumin levels increased from 26.4 g/l 
to 30.5 g/l in the study group vs 26.6  
to 28.0 g/l in the controls 
DPI, DEI and nPNA ⬆ more in the study 
group than in the controls 
Malnutrition ⬇ 6% in the controls  vs 28% 
in the study group 
Main predictor of s- albumin levels: egg 
albumin-based ONS  
and DPI. 
Leon et al.  
(2006)(158) 
Targeting several 
nutritional  
barriers (ONS was a 
small  
component of 
intervention)  
for 12 months 
HD (180) 
Albumin  
concentration  
<37 g/l 
Albumin levels: +2.1 g/l in intervention 
group vs +0.6 g/l in controls 
DEI: +4.1 kcal/kg per day in intervention 
group vs –0.6 kcal/kg per day in control 
DPI: +0.13 g/kg per day in intervention 
group vs –0.06 g/kg per day in controls. 
Cano et al.  
(2007)(149) 
ONS vs ONS + IDPN 
for 1 year 
ONS: 5.9 kcal and 
0.39 g  
protein per day 
IDPN: 6.6 kcal and 
0.26 g  
protein per day 
HD (186) 
ONS (93) 
ONS + IDPN (93) 
After 3 months: ⬆ BMI, s- albumin levels, 
and prealbumin levels in both groups 
⬆ s-prealbumin levels of >30 mg/l within 
3 months predicted  
improved 2-year survival in all patients. 
Fouque et al.  
(2008)(159) 
CKD-specific ONS 
(Renilon®,  
Nutricia, Schiphol, 
The Netherlands) vs 
standard care  
for 3 months 
HD (86) 
Case (46) 
Control (40) 
Baseline 
albumin  
concentration  
35.2 g/l in both  
groups 
⬆ DPI (P <0.01) and DEI, and improved 
subjective global  
assessment and quality of life in the group 
receiving ONS 
No difference in albumin or prealbumin 
levels between groups, but change in 
albumin and prealbumin levels correlated 
with protein intake 
Phosphatemia was unaffected and use of 
phosphate binders remained stable  or ⬇ 
*Table adapted from Kalantar-Zadeh et al. Nat rev nephrol. 2011 May 31;7(7):369-84.  Abbreviations: c-
reactive protein; DEI, dietary energy intake; DPI, dietary protein intake; EAA, essential amino acid; IPDN, 
intradialytic parenteral nutrition; nPCR, normalized protein catabolic rate; nPNA, non-protein nitrogen 
appearance; ONS, oral nutritional supplement; R, coefficient of correlation. 
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3 RESEARCH AIMS 
The overall aim of the investigations summarized in this thesis is to analyze which 
tools are more efficient in assessing nutritional status in patients with CKD and to 
evaluate the association of identified nutritional risk markers with the high mortality 
rates seen in patients with CKD. 
 
The specific aims of the studies were: 
 To investigate the impact of dialysis on appetite and the correlation between 
appetite loss and mortality in CKD5 patients starting on dialysis as well as in 
prevalent dialyzed CKD5 patients (Study I);  
 To study serum albumin and  its correlation with markers of nutritional status  
in dialysis patients (Study II); 
 To study the predictive role of IGF-1 in non-dialyzed CKD stage 5 patients and 
the mortality risk associated with IGF-1 change after initiation of dialysis 
treatment in these patients (Study III)  
 To analyze the impact of a standardized test meal on pancreatic polypeptide 
(PP) and duodenal incretin responses in HD patients (Study IV). 
 To compare readily available markers of PEW to SGA and assess their validity 
in incident and prevalent dialysis patients (Study V). 
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4 PATIENTS AND METHODS 
4.1 PARTICIPANTS AND CLINICAL COHORTS 
4.1.1 Malnutrition, inflammation, and atherosclerosis (MIA) cohort   
The MIA cohort is a cohort consisting of incident patients with CKD stage 5 (GFR<15 
mL/min) sampled close to the start of renal replacement therapy (either HD or 
peritoneal dialysis) from the renal program of the Karolinska University Hospital at 
Huddinge, Sweden. Patients are further followed up till death or transplantation. Also, 
patients are invited to attend additional visits approximately after 1 year and 2 years 
of dialysis. This ongoing prospective cohort study started in 1994, and a descriptive 
protocol has been described in more detail (160). The study exclusion criteria were 
age below 18 years or above 70 years, clinical signs of acute infection, active vasculitis 
or liver disease at the time of evaluation, or unwillingness to participate. This cohort 
constitutes the patient material included in Studies I, II, III and V (Table 5). The Ethics 
Committee of the Karolinska Institute, Sweden, approved the study (Dnr. 273/94). 
4.1.2 Mapping of inflammatory markers in chronic kidney disease (MIMICK-1) 
cohort 
The MIMICK-1 cohort is a patient population material consisting of prevalent patients 
undergoing HD at the Karolinska University Hospital at Huddinge, Stockholm (including 
as well its satellite dialysis units at Kungsholmen Södersjukhuset), Sophiahemmet, 
Danderyds Hospital and Uppsala Academic Hospital. This study originally aimed at 
investigating the variability of inflammatory parameters in prevalent HD patients over 
time. Recruitment of the patients occurred from October 2003 through March 2004. 
All patients who were receiving regular HD therapy at any of the units were invited to 
participate (n=254); 6 patients declined, and one patient with HIV infection was 
excluded. The 247 eligible patients were then followed up for 12 weeks. Eleven 
patients were excluded because of insufficient baseline clinical information; seven 
were excluded because of insufficient hs-CRP measurements; and one patient died. 
The remaining 228 patients were further followed up for assessment of overall and 
cardiovascular mortality in relation to biochemical markers, and constitutes the basis 
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of Studies I, II and V, which only contain baseline measurements. The Ethics 
Committee of the Karolinska Institutet, Sweden, approved the study (Dnr. 03/415). 
4.1.3 Mapping of inflammatory markers in chronic kidney disease (MIMICK-2) 
cohort  
The MIMICK-2 cohort comprises 84 patients from a cross-sectional study with follow-
up that originally aimed at monitoring inflammatory markers in all prevalent PD 
patients who were being controlled at the Karolinska University Hospital and 
Danderyds Hospital in Stockholm. All participants were prevalent PD patients who had 
been on continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal 
dialysis (APD) for at least 3 months. Patients were recruited from March 2008 to April 
2011. This cohort constitutes the basis of study V. The Ethics Committee of the 
Karolinska Institutet, Sweden, approved the study (Dnr. 03/415). 
4.1.4 Post study  
The Post intervention study (161, 162) was conducted between November 2005 and 
February 2008. In the study presented in this thesis, 6 clinically stable non-diabetic 
patients who had been on HD for at least 6 months and treated for at least 4 h three 
times per week using biocompatible membranes, as well as 9 HS with no known 
chronic disease or ongoing inflammation were included. Exclusion criteria were age 
under 20 or over 70 years at recruitment, pregnancy or a plan to become pregnant 
within the next 6 months, signs of infection and/or antibiotics prescribed during the 
last 4 weeks, clinically manifesting organ failure other than ESRD at the time of 
enrolment, alanine-aminotransferase (ALAT) > 2 times the normal range and/or 
neuropsychiatric illness that could affect informed consent or compliance with the 
protocol. Of the 10 patients, eight had at least one kidney biopsy before reaching 
ESRD, with four diagnosed as having hypertensive kidney disease (tubulointerstitial 
changes), three having glomerular scarring consistent with previous 
glomerulonephritis and one presenting with obstructive nephropathy after multiple 
kidney stones. Of the patients, three were taking β-blockers, four were taking calcium-
channel blockers and six were on angiotensin-converting enzyme 
inhibitors/angiotensin II receptor blockers, while none of the patients were prescribed 
statins. None of the patients were on anti-inflammatory drugs or anti-diabetics. This 
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material provided the basis for Study IV. The Ethics Committee of the Karolinska 
Institutet, Sweden, approved the study (Dnr. 2005/311-31/1; Eudra Clinical Trial 
Number 2005-004403-12). 
4.1.5 Prevalent HD patients   
Of a total of 164 prevalent patients, 128 (76 males and 52 females, median age 65 
years range 26-84 years) agreed to participate in a previous study on nutritional 
status in HD patients (8). The causes of renal failure in the 128 patients were 
diabetic nephropathy (n=23), chronic glomerulonephritis (n=38), polycystic kidney 
disease (n=13), pyelonephritis and interstitial nephritis (n=14) and other diseases or 
unknown etiology (n=40). Thirteen of the diabetic patients were insulin-dependent. 
Seventy-seven patients had signs of cardiovascular and/or peripheral vascular 
disease (grouped as CVD). Of these, 20 had suffered one or more myocardial 
infarctions, 15 had ischemic heart disease but no prior myocardial infarction, one 
had an aortic aneurysm and 11 had peripheral ischemic atherosclerotic vascular 
disease. Nineteen patients suffered from chronic heart failure. Six patients had 
cerebrovascular disease with neurological symptoms, following one or more attacks 
of stroke; all these patients also had signs of CVD. Of the 23 diabetic patients, 17 had 
CVD. Ninety-six patients had no residual renal function, defined as renal urea 
clearance <0.5 ml/min. This material was included in Study II. The Ethics Committee 
of the Karolinska Institutet, Sweden, approved the study (Dnr. 126/87). 
4.1.6 Prevalent CAPD patients   
All CAPD patients (n=36) at Huddinge University Hospital were recruited to 
participate in a previous study on nutritional status in PD (9). The patients were 
divided into two groups, based on the SGA Group I (n=11) had a normal nutritional 
status, group II (n=25) had either mild to moderate (n=16) or severe (n=9) 
malnutrition. All patients were investigated in the morning, before the first dialysate 
exchange after an overnight oral fast. Twenty-one patients (group I n=6 and group II 
n=15) were treated with a single anti-hypertensive drug or various combinations of 
the following anti-hypertensive agents: angiotensin- converting enzyme inhibitors, 
beta-blockers and calcium-blockers. Six patients were treated with diuretics. There 
were nine diabetics and all were insulin dependent. Most of the patients were 
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supplemented with sodium bicarbonate and calcium carbonate to prevent acidosis 
and hyperphosphatemia respectively. Twenty-one patients had signs of 
cardiovascular and/or peripheral vascular disease (grouped as CVD). Of these, eight 
had suffered one or more myocardial infarctions, four had ischemic heart disease 
but no prior myocardial infarction and five had peripheral ischemic atherosclerotic 
vascular disease. Two patients suffered from chronic heart failure. Two patients had 
cerebrovascular disease with neurological symptoms, following one or more attacks 
of stroke; these patients also had signs of CVD. Of the nine diabetic patients, seven 
had CVD. Thirty patients had repeated episodes of peritonitis. Of these, twelve 
suffered four or more episodes of peritonitis, eight patients in group II and four 
patients in group I. This material was included in Study II.  The Ethics Committee of 
the Karolinska Institutet, Sweden, approved the study (Dnr. 199/86). 
4.1.7 Healthy controls 
A population-based group of subjects (n= 79, 72% males, 53 (47-76) years) serving as 
controls for an ongoing study on CKD stage 3-4 patients was included for comparative 
reasons in the current thesis. This control group consisted of individuals from the 
Stockholm region who were randomly selected by Statistics Sweden (a government 
agency) and who accepted to participate, as volunteers, in the group. This material 
was included in Study V. The Ethics Committee of the Karolinska Institutet, Sweden, 
approved the study (Dnr. 40/02). 
4.2 CLINICAL AND PHYSICAL EXAMINATION 
Each patient’s medical chart was reviewed, extracting data pertaining to underlying 
kidney disease, history of CVD, diabetes, other co-morbid conditions, common 
medication and survival. CVD was defined by clinical history or signs of ischemic 
cardiac disease, and/or presence of peripheral vascular disease and/or 
cerebrovascular disease. Smoking habits were recorded as current smokers, former 
smokers and non-smokers. GFR in the MIA cohort was estimated as the mean of urea 
and creatinine clearances. In the MIMICK cohort, total time on HD was annotated as 
vintage time. 
Survival was determined from the day of examination and sample collection, with no 
loss of follow-up of any patient. Cardiovascular mortality was defined as death as a 
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result of coronary heart disease, sudden death, stroke, or complicated peripheral 
vascular disease. Causes of death were registered by a nephrologist unaware of other 
clinical or biochemical data of the patients and to the objectives of the studies. 
4.2.1 Nutritional status and PEW 
The presence of PEW and malnutrition was evaluated by SGA questionnaire (120). This 
assessment was completed either at the time of or within 1 week of blood sample 
collection and after the HD session in the MIMICK cohort. SGA includes six different 
components: three subjective assessments that are answered by the patients and 
concern the patient's history of weight loss, incidence of anorexia, and incidence of 
vomiting, and three assessments that are performed by the evaluators and are based 
on the subjective grading of muscle wasting, the presence of edema, and the loss of 
subcutaneous fat. On the basis of these assessments, each patient received a 
nutritional status score: 1 = normal nutritional status, 2 = mild malnutrition, 3 = 
moderate malnutrition and 4 = severe malnutrition. For the purpose of the studies, 
PEW and/or malnutrition was defined as SGA>1.  
The evaluation of self-rated appetite (Study I), was assessed from the SGA 
questionnaire. Regarding the self-rated appetite assessment, all patients were asked 
to grade their appetite themselves according to the following scale: 1=good, 
2=sometimes bad, 3=often bad, and 4=always bad.  
4.2.2 Intervention standardized test meal 
In the interventional study (Study IV), patients and healthy controls, following an 
overnight fast of at least eight hours, were sampled (on the day after a dialysis session 
in the case of patients). A dietician-designed meal consisting of 75 g of milk fat, 5 g of 
carbohydrates and 6 g of proteins was administered during ten minutes as a 
milkshake, immediately followed by 75 g of glucose mixed with 500 mL of purified 
water during five minutes. The meal was designed to mimic a heavy dinner in calories 
and nutrient composition. 
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4.2.3 Anthropometric evaluation 
Body composition was assessed in the cohorts and in the healthy controls by using 
skinfold thicknesses of biceps, triceps, subscapular, and supra-iliac with a conventional 
skinfold caliper (Cambridge Scientific Instruments, Cambridge, MD). Lean body mass 
(LBM) and fat body mass (FBM) were estimated by means of dual-energy x-ray 
absorptiometry (in the MIA cohort) using the DPX-L device (Lunar Corp, Madison, WI) 
or according to a theoretical formula (in the MIMICK cohort) based on skinfold 
thicknesses and body density (135). Handgrip strength was measured using a 
Harpenden Handgrip Dynamometer (Yamar, Jackson, MI, USA) in the dominant hand 
(in the incident dialysis patients) or in the hand without fistula (in the prevalent HD 
group) and normalized with measurements from healthy subjects (7). These 
assessments were completed either at the time of or within 1 week of blood sample 
collection and after the HD session in the MIMICK cohort.  
The body mass index (BMI) was calculated as weight (kg)/(height [m])2 and classified 
according to the WHO specifications.  
4.2.4 Blood samples 
In Study I, II, III and V, blood samples were collected after an overnight fast (in the MIA 
and MIMICK2 cohorts) or before the dialysis session (in the MIMICK1 cohort) after the 
longest interdialytic period. Plasma samples were kept frozen at –70 °C if not analyzed 
immediately. In these cohorts, determinations of serum creatinine, serum albumin 
(bromcresol purple), haemoglobin, hypochromic red blood cells, total, LDL- and HDL-
cholesterol, triglycerides, white blood cells count, high sensitivity C-reactive protein 
(hs-CRP) (nephelometry) and parathyroid hormone (PTH), phosphate, and calcium 
were performed by routine procedures at the Department of Clinical Chemistry, 
Karolinska University Hospital Huddinge. Other biochemical markers were analysed at 
the Research Laboratory of the Department of Renal Medicine, Huddinge. Serum IGF-
1, IGF-1 binding protein-3 (IGFBP-3), and plasma Interleukin 6 (IL-6) were measured on 
an Immulite Automatic Analyzer (DPC Corp., Los Angeles, CA). The intra-assay 
coefﬁcient of variation for IGF-1 was 4.3%, and the interassay coefﬁcient of variation 
was 6.9%. IGFBP-1 was analyzed by ELISA (IEMA Test; Medix Biochemica, Kauniainen, 
Finland). Intact ﬁbroblast growth factor-23 (FGF-23) was measured with ELISA (Kainos 
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Laboratories International, Tokyo, Japan). Serum osteoprotegerin (OPG) was analyzed 
by ELISA (R&D Systems Inc., Minneapolis, MN).  
In Study IV, blood samples were collected at 0 min, 30 min, 60 min, 120 min and 240 
minutes after meal intake in both HD patients and HS. Plasma and serum were 
extracted immediately and subsequently frozen at -80°C until analysis. The plasma 
levels of pancreatic polypeptide (PP) and cholecystokinin-8 (CCK-8) were measured by 
enzyme-linked immunosorbent assay (ELISA) with kits from Millipore Corporation (St. 
Charles, MO, USA) and Wuhan EIAab Science Co., Ltd (Wuhan, China), respectively. 
Serum total glucose-dependent insulinotropic polypeptide, GIP (1–42 amide and 3–42 
amide) and plasma active glucagon-like peptide 1, GLP-1(7–36 amide and 7–37 amide) 
levels were measured by high sensitivity photometric ELISA (Millipore, St Charles, MO, 
USA). Each measure was repeated two times for each peptide and only accepted 
coefficient of variation (CV) lower that 10%. PP, GIP and GLP-1 had CV lower than 10%, 
but not CCK8 so it was excluded from the study. Serum concentrations of insulin were 
determined using an Immulite Automatic Analyzer (Siemens Medical Solutions 
Diagnostic Products, Los Angeles, CA, USA). Serum glucose and triglycerides were 
measured using routine methods at the Department of Laboratory Medicine, 
Karolinska University Hospital.  
4.2.5 Statistical analyses 
All statistical analyses were performed using statistical software SAS version 9.4 (SAS 
Campus Drive, Cary, NC, USA 27513). Normally distributed variables were expressed 
as mean ± SD and non-normally distributed variables were expressed as median and 
range (minimum and maximum) or interquartile range (10th-90th or 25th-75th 
percentile, IQR). Also, categorical values were expressed as number and percentage, 
unless otherwise indicated. Statistical significance was set at the level of p< 0.05.  
Comparisons between two groups were assessed with the Student’s unpaired t-test 
and Mann-Whitney test or 2 test, as appropriate. Differences among more than two 
groups were analyzed by analysis of variance (ANOVA) using one-way ANOVA or 
Kruskal-Wallis test, as appropriate. As many values were not normally distributed, 
Spearman’s rank correlation () was used to determine univariate correlations. 
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Multivariate associations were performed by multiple regressions, stepwise multiple 
regressions and multinomial logistic regression analyses.  
To evaluate the sensitivity and specificity of selected parameters as predictors of 
mortality, Receiving Operator Characteristics (ROC) curve analyses were performed 
(163). The optimum cut-off value, with the combination of the highest sensitivity and 
specificity, was calculated. 
Survival analyses were made with the Kaplan-Meier survival curve or the Cox 
proportional hazard model. The relative risks for mortality were determined by 
multivariate Cox regression analysis and presented as hazard ratio (HR; 95% 
confidence intervals (CI))  
4.3 STUDY PROTOCOLS 
Table 5. Description of the studies included in the thesis 
Study Cohort Subjects Outcome 
I MIA 
MIA (1 year follow-up) 
280 
243 
 
 
Changes in self-rated appetite status; all-
cause mortality  
II MIA 
MIMICK-1 
HD 
CAPD 
458 
222 
125 
36 
 Predictive value of s-albumin as a 
marker of nutritional status 
III MIA 
MIA (1 year follow-up) 
 
365 
207 
Changes in IGF-1 levels after initiation of 
dialysis; its correlation with bone 
metabolism, nutritional status and 
mortality.  
IV POST  STUDY 
CONTROL 
6  
9  
 Effect of test meal in appetite regulating 
hormones (PP, GIP and GLP-1) 
V MIA 
MIMICK-1 
MIMICK-2 
CONTROL 
399 
211 
78 
79 
 Predictive value of commonly used 
markers of PEW (HGS, s-creatinine, s-
albumin, cholesterol)  
 
Study I is a post-hoc, cross-sectional observational study of prevalent patients with 
CKD stage 5, including both those on maintenance dialysis (CKD5-D) and those not yet 
on dialysis (CKD5-ND). Self-rated appetite, along with anthropometrics and 
biochemical markers of nutritional status, were measured and related to all-cause 4-
year mortality as assessed by Kaplan–Meier survival curves and the Cox proportional 
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hazards model.  Study I shows that self-rated appetite is not an independent predictor 
of 48-months survival in most patients with CKD 5-D. 
Study II evaluates, again in a post-hoc, cross-sectional observational study, the use of 
serum albumin as a risk marker for malnutrition in two relatively large cohorts of 
incident and prevalent CKD stage 5 patients. Serum albumin measured using a 
common methodology (bromocresol purple) was related to other markers of 
nutritional status, including other biochemical markers, clinical anthropometrics, and 
densitometry (dual-energy x-ray absorptiometry). Analyzing data from 458 incident 
and 383 prevalent dialysis patients, we found that serum albumin correlates poorly 
with other markers of nutritional status. Thus, its value as a reliable marker of 
nutritional status appears limited. 
Study III evaluates, in a post-hoc, cross-sectional observational study, the use of IGF-1 
as a risk marker for malnutrition and PEW measured using SGA in a large cohort of 
prevalent dialysis patients. Serum IGF-1 was related to other biochemical, clinical, and 
densitometric markers of nutritional status and mineral and bone metabolism in 365 
clinically stable patients and its’ predictive value for 5-year mortality risk was tested 
using log-rank test. The study shows that low serum IGF-1 associates with a sarcopenic 
body composition and with markers of disturbed bone metabolism, while also 
predicting an increased risk of mortality. 
Study IV is a post-hoc analysis of data from a randomized, controlled intervention 
testing the impact of a fat- and carbohydrate-rich meal on biochemical markers of 
oxidative stress and inflammation. Using stored samples, we assessed changes in the 
appetite regulating peptide hormones pancreatic polypeptide (PP), glucose-
dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) in HD 
patients and healthy controls during the 4 first 4 hours after consuming a meal. Six HD 
patients and 9 healthy subjects (HS) received a standardized test meal. Fasting and 
postprandial circulating levels of peptide hormones were measured using commercial 
enzyme-linked immunoassays (ELISAs), while glucose and triglycerides were assessed 
using conventional clinical chemistry methods. The study shows that fasting levels of 
both PP and GIP levels are both elevated in HD patients as compared to controls, as is 
the postprandial PP response. We speculate that this may be one mechanism whereby 
CKD engenders poor appetite. 
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Study V uses three cohorts (399 incident CKD5 patients starting on dialysis, 211 
prevalent HD and 78  prevalent PD patients) to compare, in a post-hoc, cross-sectional 
observational study, common markers of nutritional status for assessing PEW as 
defined by SGA score. Using three separate multivariate regression models, we tested 
the relative predictive values for changes in SGA to predict changes in common clinical 
and biochemical markers of PEW. We report that serum levels of albumin, creatinine, 
and cholesterol as well as handgrip strength are in general only weakly or not at all 
associated with PEW as assessed by SGA following correction for cofounders.  
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5  RESULTS AND DISCUSSIONS 
5.1 OVERVIEW 
Both malnutrition (defined as a state of nutrient deficiency secondary to diet patterns) 
and protein-energy wasting (PEW, defined as a state of body protein catabolism and 
insufficient energy intake secondary to chronic renal disease), usually occurring 
together in CKD and here used as interchangeable entities, are common in CKD 
patients, where they also are strongly associated with low-grade inflammation and an 
adverse outcome (1-7). The main goal of this thesis was to investigate the relative 
usefulness of clinically available tools to accurately identify and monitor PEW and 
malnutrition in CKD as identifying patients at risk is a goal in itself and also a 
prerequisite for interventional therapies and prioritization of resources. By studying a 
broad spectrum of renal diseases of patients with reduced glomerular filtration rates 
but not yet on dialysis, as well as patients on both HD and PD, we increase the 
practical applicability of our results in the clinical setting. Unfortunately, our data do 
not support the use of any one single marker for the unequivocal identification of 
malnourished CKD patients, and even less makes it likely that commonly used 
methods can be clinically useful for risk stratification. Instead the results of our studies 
suggest that a panel combining several markers and including ideally also SGA should 
be used if possible. Thus, further studies are urgently needed to identify and validate 
better and more reliable tools to assess and monitor nutritional status in various CKD 
populations.  
5.2 MEASURING SELF-RATED APPETITE TO ASSESS NUTRITIONAL STATUS   
Anorexia is thought to be an important driver of malnutrition and PEW, with studies 
suggesting a prevalence of subjective anorexia of between 35% and 50% in different 
CKD populations (73-75). Anorexia appears to be more common in CKD patients with a 
low GFR . Both Kalantar-Zadeh et al. (164) and Carrero et al. (165) investigated 
maintenance HD patients and found that simply reporting a moderately or severely 
decreased appetite as part of SGA questioning was associated with a greater risk of 
mortality over 15 and 19 months respectively of follow-up, even after adjustment for 
age, sex, inflammation, dialysis vintage, and co-morbidity (164, 165). Interestingly, 
 34 
both studies (164, 165) and clinical experience suggests that most CKD patients 
improve their appetite following the start of dialysis (49), suggesting that the already 
mentioned studies select patients whose anorexia is in fact therapy resistant or who 
may be under-treated. To our knowledge, no systematic studies of the relation 
between self-rated appetite and mortality have been reported in CKD stage 5 patients 
not yet on dialysis (CKD5-ND). 
In Study I, we investigated the impact of dialysis on appetite, predictors of appetite 
loss, and the correlation between appetite loss and mortality in a cohort of CKD5-ND 
patients starting on dialysis, as well as in prevalent dialyzed CKD stage 5 patients 
(CKD5-D) undergoing maintenance PD or HD . Our main finding in Study I was that 
among CKD5-ND patients, mortality during the four-year follow-up period did not 
differ between those with a self-rated poor appetite and those with a good appetite at 
baseline. When analyzing patients on dialysis therapy, a poor appetite predicted 
mortality risk in PD patients, but not in HD patients (Figure 2).  
 
Figure 2. Cox proportional hazards from three models (non-adjusted crude model, 
Model 1 with adjustment for age and gender; and Model 2 with adjustment also for 
co-morbidities (DM and CVD) and dialysis vintage or GFR) of mortality risk during 48 
months of follow-up in CKD5-ND (n=280), PD (n=127) and HD (n=116) patients. CR, 
competing risk analysis. 
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Of interest, when analyzing changes in self-rated appetite in those patients who were 
investigated longitudinally (both before start and on maintenance dialysis), the 
proportion of patients who reported a poor appetite after the start of dialysis 
increased significantly amongst HD patients, whereas the changes in appetite in PD 
patients were not significant (Figure 3). This discrepancy is surprising for two reasons. 
First, it opposes the prevailing view that initiation of HD is associated with an 
improvement in appetite along with an increased food intake due to the relaxations of 
dietary restrictions. Second, patients on PD have been reported to be at greater risk of 
anorexia due to feelings of fullness due to the presence of dialysate in the abdomen, 
as well as a central glucose load that may reduce the drive to eat (166). Indeed, PD 
patients have been reported to have a lower food intake than both HD patients and 
healthy controls (167). A poorer appetite in PD patients may be a surrogate marker of 
more intensive therapy and/or a high glucose load, possibly indicating that hypertonic 
solutions were needed to increase a poor peritoneal ultrafiltration, factors all linked to 
a poor survival in PD patients (168) (169, 170). It is also possible that the finding that 
self-rated appetite did not decrease in patients on PD reflects a selection bias, as 
patients starting PD had less co-morbidity than those starting HD. 
 
Figure 3. Appetite status in 151 CKD5-ND patients who had been investigated both 
before start of dialysis and after about one year of dialysis treatment with PD (n=91) 
or HD ( n=60).  
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5.3 MEASURING BIOCHEMICAL MEDIATORS OF APPETITE TO ASSESS 
NUTRITIONAL STATUS 
Previous studies have demonstrated that CKD is often associated with abnormal 
circulating levels of bio-molecules that have been implicated in the regulation of 
energy expenditure, appetite regulation and body composition. These include leptin, 
ghrelin (171-173) and adiponectin (171, 173, 174), leading us (79, 175) to 
hypothesize that poor appetite in uremic patients may be partly due to an 
accumulation of anorexigenic and catabolic substances, some of which may be at 
least partly removed through dialysis.  
Physiologically, the short-term regulation of appetite and satiety happens at a 
gastrointestinal level through the central and local effects of peptide hormones 
secreted by intestinal cells, as well as through the action of the nervous system 
(176). Peptide hormones released by the gut to  induce satiety and thus limit food 
intake include PP, GIP, GLP-1, and CCK (177). These and other peptides secreted by 
gastrointestinal cells are also important regulators of gastric motility, and have 
previously been reported to be elevated in dialysis patients (178). Thus, this mode of 
appetite regulation is of particular interest in the CKD population, whose meal size is 
reduced and who eat more slowly, while experiencing an increased feeling of satiety 
already before meals (179). Also, some of the anorexigenic peptides have recently 
been reported to be elevated in the blood of CKD patients receiving dialysis (180, 
181). Although impaired tubular metabolism of these molecules likely plays a role in 
their increased concentrations, the consequences of this increase as well as the 
putative role of other anorexigens acting through the gut remain unknown (78, 182-
184). 
Therefore, we investigated in a post-hoc analysis of samples from a previous 
interventional trial the response of PP and other incretins (GIP and GLP-1) to a fat 
and carbohydrate – rich meal in HD patients (Study IV) (161, 162). In the 6 HD 
patients investigated, the basal concentrations of blood PP were much higher in 
fasting HD patients than in fasting 9 healthy subjects (Figure 4). Furthermore, 
following a meal, blood concentrations of PP increased significantly more in the HD 
patients than did blood concentrations in the healthy subjects (in whom changes in 
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PP were negligible). Suggesting a physiological significance rather than a reflection of 
reduced renal clearance, the other gastrointestinal peptides studied, GIP and GLP-1, 
did not exhibit a similar postprandial increase in either group. 
Figure 4. Area under the curve (AUC) of PP concentrations in healthy subjects (HS) 
and H 
 
While dynamic changes of these molecules in response to feeding have not to our 
knowledge been studied previously in HD patients, it has been speculated that an 
observed elevation of PP may be one of multiple etiologies contributing to the high 
prevalence of anorexia in HD patients (48, 78, 165, 170, 185).  Similar to our findings, 
Henriksen et al. (186) found that PP levels were significantly higher in 10 patients 
with moderately decreased renal function as compared to 10 healthy controls. 
Physiologically, PP is secreted by endocrine cells at the periphery of pancreatic islets 
(187). The presence of protein and fat derived from dietary intake is the major 
stimulus for the release of PP. Administering synthetic PP to human test subjects 
resulted in a decreased appetite and food intake, whereas little effect was found on 
gastric emptying (188). Taken together with this finding, our results suggest that 
analysis of PP could potentially be of value when investigating anorexia as a cause 
for PEW in CKD patients. Unfortunately, we were not able to measure PP levels in 
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the cohort studies (Study I-III, and Study IV) while in Study IV the original protocol 
did not assess self-rated appetite. Future studies are warranted to ascertain if 
patients with elevated circulating levels of PP also report a poor appetite, and what 
happens to PP levels if appetite changes.  
5.4 MEASURING S-ALBUMIN TO ASSESS NUTRITIONAL STATUS IN CKD 
Despite the large body of evidence demonstrating the uselessness of serum albumin 
levels as an accurate  marker of nutritional status in CKD (14) (189), it is still  the most 
widely used method to assess nutritional status in both the clinical and research 
settings (86). It was traditionally assumed that s-albumin concentrations in the blood 
primarily reflected hepatic amino acid availability, and that it thus would function as 
an indicator of nutritional status (86). However, while blood albumin levels are 
predominantly low in CKD patients, this is not a reflection of malnutrition for several 
reasons (107). First, albumin is an acute phase reactant; thus, s-albumin levels in 
dialysis patients are strongly associated with inﬂammation (105). Second, blood 
albumin concentration varies with the amount of intravascular fluid; therefore 
overhydration, which is common in these patients, can disguise the real concentration 
of s-albumin. Third, the impact of hepatic protein restriction on circulating albumin is 
limited by albumin´s considerable half-life (up to 20 days) and abundance (100). Thus, 
even in extreme cases of malnutrition - such as marasmus and anorexia nervosa - s-
albumin levels tend to remain normal (101). Indeed, in the Minnesota study (190) an 
induced, prolonged starvation elicited multiple compensatory changes in the healthy 
participants, but s-albumin levels declined only marginally. Thus, given the above 
findings and data demonstrating a similar plasma albumin degradation rate in CKD 
patients as in healthy individuals (191), it would be surprising if malnutrition was the 
main factor influencing serum albumin in CKD. Instead, as summarized above, 
circulating albumin levels in CKD patients are likely most strongly related to common 
co-morbidities, fluid overload and, especially, low grade inflammation  (192). 
Another important determinant of blood albumin particular to CKD is illustrated in 
Study II, where we report that urinary albumin excretion is the strongest predictor of 
s-albumin levels in incident dialysis patients with residual renal function. The same 
study did not show any strong associations between nutritional status and s-albumin 
in either incident or prevalent dialysis patients. Whereas s-albumin was weakly 
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associated with SGA score, there were negligible associations of s-albumin also with 
other markers of nutritional status, such as HGS and LBM (Figure 5). 
 
Figure 5. The predictive strength (expressed as pseudo r for SGA and r2 for HGS, 
LBMDEXA, LBMAnthropometrics and BMI) of available information of traditional clinical 
factors (Model 1), Model 1 + serum albumin (Model 2) and when using all available 
nutritional information (Model 3), for the prediction of the variability of different 
nutritional markers in incident and prevalent dialysis patients.  
 
Traditional factor = age, gender, diabetes and CVD. Other factor= all additional available information about 
nutritional status: SGA, hand grip strength, lean body mass (estimated by two methods), BMI, hsCRP and smoking. 
 
Instead, Study II suggests that urinary albumin losses, and inflammation (as assessed 
by hsCRP) are much more important determinants of s-albumin levels in the dialysis 
setting (Figure 6). Indeed, while inflammation, usually assessed as hsCRP, is well 
described to associate with malnutrition and atherosclerosis in the MIA syndrome (32, 
160), there are direct causal pathways linking a low albumin to inflammation (165). 
Furthermore, many studies have shown that inflammation is consistently associated 
with low levels of s-albumin in uremia, regardless of nutritional state (53, 54).  
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Figure 6. Box plot of serum albumin by nutritional status in inflamed and non-
inflamed, incident (Panel A; n=429) and prevalent dialysis patients (Panel B; n=380).  
 
5.5 MEASURING SERUM CREATININE TO PREDICT NUTRITIONAL STATUS IN CKD 
Clinically, besides serum albumin, the biomarker most commonly used for assessing 
nutritional status in CKD patients is serum creatinine (193). As a proxy of lean body 
mass, s-creatinine is believed to reflect patient´s nutritional status.  While this may 
seem unintuitive given the role of s-creatinine as a key marker of glomerular filtration, 
it has been shown that it indeed correlates with markers of nutrition (194). In Study V, 
we were able to compare these two common biomarkers, and report that s-creatinine 
predicted SGA score to the same (albeit low) degree as did serum albumin, but that 
the former was less affected by inflammation (assessed as hsCRP) than was the latter. 
By now there is enough evidence in literature (110, 194, 195) reporting the successful 
use of s-creatinine as a cost-effective, reliable and commonly available biomarker of 
muscle mass in stable dialysis patients. For example, a recent review by Patel et al. 
(110) reported that s-creatinine correlates well with several other markers of muscle 
in stable dialysis patients. However, few of these studies have investigated s-
creatinine as a predictor of nutritional status rather than of muscle mass (194), while 
changes in s-creatinine during and between dialysis sessions makes easy 
interpretation and use of s-creatinine as a routine marker of nutrition difficult. In 
Study V, we found based on bivariate correlations in incident dialysis patients and 
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prevalent HD patients, that s-creatinine was weakly associated with signs of PEW 
(SGA>1) in male and female patients.  
It is possible that measuring creatinine appearance in urine would represent a further 
improvement; however, this was not explored in the current study.  
5.6  ANTHROPOMETRIC MEASUREMENTS TO ASSESS NUTRITIONAL STATUS 
Anthropometrics has been used to assess nutritional status clinically in several 
populations (193, 196, 197) . Over time, a multitude of different measurement 
methods have been developed and proposed – including BMI, HGS, skinfold thickness, 
arm circumference, waist circumference and others. Unfortunately, most 
anthropometric measurements have to be used with caution when used to assess 
nutritional status or PEW in CKD patients as markers of body composition, such as 
lean muscle and bone mass, fat tissue are often altered in these patients due to 
numerous factors other than nutritional and metabolic alterations commonly 
observed in patients with CKD such as fluid retention.   
When such a correlation was evaluated in Study V, we were only partly able to 
replicate the previously reported association between a low HGS and SGA>1 in CKD 
(14). In this study, we were able to show a robust association only in incident dialysis 
patients, with a weak association in prevalent PD patients and no association at all in 
prevalent HD patients. This discrepancy may be partially explained by the age 
difference amongst cohorts: incident dialysis 55(35-68) years; prevalent HD 66(42-80) 
years; prevalent PD 64(43-80) years and controls 53(47-76) years, as well as the 
association between HGS and s-creatinine in two of the cohorts, potentially leading to 
over adjustment in our multivariate model.  
Finally, SGA remains one of the most well established and commonly used methods 
for identifying patients with PEW in clinical research settings (85). However, in daily 
clinical practice its use is limited by its lack of specificity (e.g. self-reported loss of 
appetite and visual signs of sarcopenia), subjective nature, the time it takes to 
perform and its’ dependence on trained dietitians or nurses, as well as the 
confounding introduced by reported inter-individual (and also intra-individual) 
variation amongst assessors. The problem is well illustrated by Ek et al., who in 90 
patients aged 70 years of age or older employed two independent observers to 
administer SGA. When the data was analyzed, the main determinant of SGA was 
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found to be the experience of the assessor (198). For these and other reasons, it is 
important to continue the search for reproducible and easily available techniques to 
assess malnutrition and PEW separately and specifically.  
5.7 CAN IGF-1 BE A BETTER BIOMARKER OF NUTRITIONAL STATUS IN CKD? 
As discussed, we lack a reliable tool or biomarker to assess and monitor PEW in CKD. 
Serum IGF-1 has long been used as a marker of hypothalamic anabolic signaling in the 
setting of pediatric CKD, especially during treatment with exogeneous anabolic drugs 
(199). IGF-1 levels in the blood have also been proposed as a marker of nutritional 
status and food intake in patients with ESRD (15, 113). Indeed, IGF-I has been reported 
to be a useful marker of under-nutrition in prevalent HD patients (113). However, to 
our knowledge no large-scale studies have evaluated IGF-1 as a marker of PEW in CKD 
patients.    
Physiologically, IGF-1 functions as the downstream effector molecule mediating 
growth hormone (GH) action in body tissues. In the short-term, IGF-1 signaling 
regulates protein and carbohydrate metabolism whereas its long-term actions 
concern cell proliferation, differentiation and anti-apoptotic mechanisms (200).  
Serum levels of IGF-1 are directly determined by GH release, which in turn is a factor 
of age (201), genetic traits (202), nutritional and health status (203, 204). In a setting 
of insufficient food intake, IGF-1 levels are low (205) but rise rapidly upon re-feeding 
(206, 207). Also, in populations such as postmenopausal women, serum IGF-1 
concentrations correlate with lean body mass (208). Furthermore, in the HERITAGE 
Family Study, an IGF-1 gene polymorphism was associated with both body fat mass 
and fat free mass (209). Indeed, a previous study from our group (210) found that IGF-
1 appear to correlate well with markers of PEW. 
Given the encouraging data and the clear rationale, we investigated the association 
between circulating IGF-1 and PEW of CKD patients in Study III. We report an inverse 
association between IGF-1 and PEW as assessed by SGA. In addition, we found that 
body fat mass associated with IGF-1 variation during the first year on dialysis, but 
could not find an association of IGF-1 with lean body mass. However, like s-albumin, 
IGF-1 levels were also influenced by inflammation. Indeed, in Study III, we found that 
IGF-1 levels were negatively related to inflammation (IL-6, ß=-0.13, p<0.05). Taken 
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together, these findings suggest that the value of s-IGF-1 as a marker of nutritional 
status in CKD patients may be limited. 
Also of interest in Study III, there was a significant increase in IGF-1 during the first 
year on dialysis therapy, and those patients who exhibited a persistently high or 
increasing level of IGF-1 had a lower risk of all-cause mortality than did those with a 
low or decreasing IGF-1 (Figure 7). These effects were independent of pre-existing risk 
factors including age, CVD, diabetes, inflammation and PEW. Thus, it would appear 
that the predictive value of IGF-1 on mortality in dialysis patients is not necessarily 
related to PEW. To the best of our knowledge, just a few previous studies have 
evaluated the predictive value of IGF-1 on mortality in renal disease patients. These 
have reported that serum IGF-1 predicts short-term mortality in intensive care unit 
patients with acute kidney injury  (211). Also, consistent with Study III, a cross-
sectional study including 127 prevalent HD patients with up to 36 months of follow-up 
reported an inverse association between IGF-1 levels and all-cause mortality (7), while 
a low IGF-1 has been associated with mortality in 64 HD patients followed for 24 
months (212).  
 
Figure 7.The Kaplan-Meier curves of five year survival of 207 patients who had 
persistently high or increased IGF-1 levels or persistently low or decreased IGF-1 levels 
during their first year on dialysis. 
 
Clearly, the mechanism(s) whereby a high IGF-1 may reflect a positive prognosis in 
CKD patients remains to be elucidated. One may assume that the role of IGF-1 as a key 
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mediator of anabolism is important. However, it is of interest to note that one study 
reported that short-time administration of recombinant human IGF-1 (rhIGF-1) could 
improve glomerular filtration rate and promote anabolism in PD patients with a poor 
nutritional status (213). A similar effect has been reported in a rat model of acute 
ischemic injury, where rhIGF-1 was apparently able to accelerate the recovery of renal 
function and reduce the rate of tissue catabolism (214). However, the efficacy and 
long-term clinical usefulness of GH or rhIGF-1 therapy in CKD patients is still very much 
unclear. 
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6 WHERE DO WE GO FROM HERE? 
The present thesis attempts to find out which tools current in use to assess and 
monitor nutritional status and PEW reflect “true” nutritional status in the clinical 
and research setting. Due to budget restraints and the limited time that can be 
devoted to nutritional assessments, an ideal marker of nutritional status should not 
only be accurate, but also inexpensive, easy to use, and widely available (Table 6). As 
the cross-sectional nature of our studies precludes conclusions regarding causality, 
ideally the next steps ought to be to initiate longitudinal, interventional and 
mechanistic research attempting to identify marker(s) that appropriately reflect 
changes in nutritional status. 
 
Malnutrition and PEW have been shown to lead to poor outcome – not only in 
patients with kidney disease, but also in other diseased population as well as in the 
general population. Due to its multifactorial etiology, it is not always simple to detect 
and thus treat such maladies. Therefore, it is recommended that more clear and 
feasible guidelines are developed that are easy to follow and compatible with the 
reality of most clinical practices. The latest guidelines to diagnose and monitor PEW 
have been developed by a committee of renal nutrition experts (20). Despite detailed 
description on the used criteria to assess PEW, adherence to this guideline seems to 
be supremely difficult. Indeed, most studies use only one suggested criteria (usually, 
SGA, MIS or s-albumin) to measure PEW (35, 39, 42, 44); even though, it has been 
agreed that PEW is best detected by use of multiple tools including but not limited to 
circulating biomarkers, markers of body composition such as BMI, percentage of body 
fat, mid-arm circumference, creatinine appearance, or description of current dietary 
intake. Therefore, there is a need for a longitudinal study with frequent follow-up 
(such as every third month), assessed by experienced renal dieticians; such studies are 
lacking at present.   
 
Despite that several intervention studies have shown that nutritional supplementation 
can ameliorate and even revert PEW (81), none have lasted more than 12 months. In 
addition, while one year may be enough to see some changes in body composition 
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and other  parameters of nutritional status, it is still unknown what would be the long-
term effects of these interventions and if continuous use should be advocated. In 
addition, muscle wasting, a common consequence of PEW, can be mitigated by 
increased frequency of physical activity especially anaerobic exercises. It has been 
reported that a clinical intervention combining administration of an anabolic steroid 
(nandrolone decanoate) (215) and resistance training during dialysis sessions three 
times a week for 12 weeks produced anabolic effects and improved physical 
functioning in HD patients (216). Moreover, there is enough evidence in the literature 
to show that exercise training for patients with CKD has multiple benefits beyond the 
improvement of physical function (217). However, these intervention studies also only 
lasted up to 18 months. Therefore, the need of longitudinal randomized interventions 
including optimum nutritional intake and adequate physical activities levels must be a 
priority in order to discover which therapy combination will ensure the best results in 
improving nutritional status and PEW as well as increase chances of survival.   
 
Table 6. Characteristics of good marker of nutritional status in CKD patients  
 Characteristics of good marker of nutritional status  
 
Simple to measure, inexpensive and available locally 
Correlates with SGA and other markers of nutritional status 
Marker unaffected by disease (except malnutrition) 
Strong prognostic value 
Uninfluenced by immediate food intake  
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7 CONCLUSION 
One main conclusion of this thesis is the relatively poor correlation of existing 
biomarkers of nutritional state to the current standard assessment method – SGA. 
This suggests an urgent need to find an objective method consistent both with clinical 
risk and epidemiological outcomes to assess nutritional status in patients with CKD. 
Furthermore, our studies suggest that while SGA certainly captures aspects of both 
malnutrition and PEW in CKD, the exact aspects as well as their potential overlap 
remain to be clarified. However, until a better tool is validated, the careful evaluation 
of well-trained renal dietitians employing approaches such as SGA remains the best 
available method to detect and follow nutritional abnormalities in the CKD population. 
 
 Study 1: The subjective variable self-reported appetite may be of limited 
value in the clinical setting as an independent predictor of mortality risk in 
CKD5-ND patients, and in dialysis patients it may be a weaker predictor than 
previously thought.      
 
 Study 2: As expected, s-albumin correlates poorly with other validated and 
more reliable methods of assessment in nutritional status. Indeed, as 
previously published by us and others, s-albumin is more a marker of 
inflammation and disease. In this publication, we aimed to demystify the 
fame of s-albumin as a strong and reliable marker of malnutrition. It is not, 
and should not be used as such!  
 
 Study 3: In incident dialysis patients, low serum IGF-1 associates with body 
composition and markers of mineral and bone metabolism, and it predicts 
increased mortality risk. 
 
 Study 4 The fasting PP and GIP levels, and the postprandial PP response, 
were markedly higher in HD patients compared to HS whereas postprandial 
responses of glucose, triglycerides, GIP and GLP-1 were similar in patients 
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and HS. We speculate that an elevated PP response may be involved in the 
commonly observed prolonged feeling of fullness and poor appetite of this 
patient population. 
 
 Study 5: Using three separate multivariate regression models to investigate 
the relative predictive value for SGA of changes in common clinical and 
biochemical parameters, we confirm in this study that readily available 
markers of PEW, s-albumin, s-creatinine, cholesterol and HGS, are in general 
only weakly or not at all independently associated with PEW as assessed by 
SGA. 
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8 STRENGTHS AND LIMITATIONS 
8.1 STRENGTHS 
Our analyses have a number of strengths, mainly the detailed phenotype of our 
patient materials and a long follow-up time. Another advantage, not always 
considered in epidemiological studies, is that we censored for transplantation in our 
survival analysis; restoration of renal function cancels the prospective risk of dying. 
The cross-sectional nature of the studies in the present thesis does not allow us to 
infer causality from the results. However, in studies on etiology, diagnosis, or 
prognosis and adverse effects, observational studies are much more valid than 
randomized controlled trials (218). 
8.2 LIMITATIONS 
There are several limitations of these studies. First of all, it should be noted that there 
is no easily available gold standard method that unequivocally could define nutritional 
status – and such method may not even exist. Thus we and others have to rely on 
imperfect methods which are influenced by factors other than nutrition. It is 
important to acknowledge that body weight, skinfold thicknesses and DEXA may all be 
affected by hydration status in the studied patients (219). In fact, BMI may not reflect 
real nutritional status, as gross imbalance in fluid status in CKD patients may cloud the 
results. Furthermore, SGA is widely used in clinical and research practice and has been 
shown to predict outcome in dialysis patients (220); however, as a subjective tool, SGA 
cannot verify questions that may have been under- or over-reported. In addition, 
despite relying on well-trained nurses to perform the SGA assessments, one should 
keep in mind that the existence of intra- and inter-individual divergences may exist. 
Indeed, the inter-interviewer agreement of SGA is about 70% (122). Despite being 
validated against the gold standard method  for nutritional assessment of body 
protein stores, total body nitrogen level, SGA could only differentiate severely 
malnourished patients from patients with normal nutrition whereas the exact degree 
of malnutrition could not be ascertained (122). In the studies contained in this thesis, 
we have not used the malnutrition gradation. Instead we dichotomized this variable 
into presence (SGA>1) of malnutrition or PEW signs, or not.  
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